From Financial Modeling Prep: 2025-05-02 07:00:00

In summary, Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focusing on innovative therapies for cancer and rare diseases. The stock has a stable consensus price target of $12, with an upgraded Zacks Rank #2 (Buy) indicating improved earnings potential. Investors should track clinical trials, regulations, and partnerships for future performance insights.



Read more at Financial Modeling Prep:: Protara Therapeutics, Inc. (NASDAQ:TARA) Overview